155 related articles for article (PubMed ID: 36652274)
1. Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?
Gisbert JP; Chaparro M
J Crohns Colitis; 2023 Jun; 17(6):995-1009. PubMed ID: 36652274
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero.
Goulden B; Chua N; Parker E; Giles I
Rheumatology (Oxford); 2022 Oct; 61(10):3902-3906. PubMed ID: 35258557
[TBL] [Abstract][Full Text] [Related]
3. Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children.
Liu Z; Julsgaard M; Zhu X; Martin J; Barclay ML; Cranswick N; Gibson PR; Gearry RB; van der Giessen J; Connor SJ; Rosella O; Grosen A; Toong C; Flanagan E; Wieringa JW; Janneke van der Woude C; Bell SJ;
J Crohns Colitis; 2022 Dec; 16(12):1835-1844. PubMed ID: 35779236
[TBL] [Abstract][Full Text] [Related]
4. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
[TBL] [Abstract][Full Text] [Related]
5. Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review.
Gisbert JP; Chaparro M
Drugs; 2020 Jul; 80(11):1085-1100. PubMed ID: 32562207
[TBL] [Abstract][Full Text] [Related]
6. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network.
Fitzpatrick T; Alsager K; Sadarangani M; Pham-Huy A; Murguía-Favela L; Morris SK; Seow CH; Piché-Renaud PP; Jadavji T; Vanderkooi OG; Top KA; Constantinescu C;
Lancet Child Adolesc Health; 2023 Sep; 7(9):648-656. PubMed ID: 37390832
[TBL] [Abstract][Full Text] [Related]
7. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines.
Beaulieu DB; Ananthakrishnan AN; Martin C; Cohen RD; Kane SV; Mahadevan U
Clin Gastroenterol Hepatol; 2018 Jan; 16(1):99-105. PubMed ID: 28870657
[TBL] [Abstract][Full Text] [Related]
8. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
Mitrova K; Pipek B; Bortlik M; Bouchner L; Brezina J; Douda T; Drasar T; Klvana P; Kohout P; Leksa V; Minarikova P; Novotny A; Svoboda P; Skorpik J; Ulbrych J; Veinfurt M; Zborilova B; Lukas M; Duricova D;
J Crohns Colitis; 2022 Dec; 16(12):1808-1815. PubMed ID: 35708729
[TBL] [Abstract][Full Text] [Related]
9. Safety of first year vaccination in children born to mothers with inflammatory bowel disease and exposed in utero to anti-TNFα agents: a French nationwide population-based cohort.
Luu M; Benzenine E; Barkun A; Doret M; Michiels C; Degand T; Quantin C; Bardou M
Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1181-1188. PubMed ID: 31617226
[TBL] [Abstract][Full Text] [Related]
10. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.
Julsgaard M; Christensen LA; Gibson PR; Gearry RB; Fallingborg J; Hvas CL; Bibby BM; Uldbjerg N; Connell WR; Rosella O; Grosen A; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Connor SJ; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K; Bell SJ
Gastroenterology; 2016 Jul; 151(1):110-9. PubMed ID: 27063728
[TBL] [Abstract][Full Text] [Related]
11. New drugs for the treatment of IBD during conception, pregnancy, and lactation.
Pugliese D; Privitera G; Gisbert JP; Chaparro M
Dig Liver Dis; 2024 Feb; 56(2):235-241. PubMed ID: 37718225
[TBL] [Abstract][Full Text] [Related]
12. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
[TBL] [Abstract][Full Text] [Related]
13. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.
Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S
Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Vaccination Effective in Children Exposed to Anti-Tumour Necrosis Factor Alpha in Utero.
de Lima A; Kanis SL; Escher JC; van der Woude CJ
J Crohns Colitis; 2018 Jul; 12(8):948-953. PubMed ID: 29726943
[TBL] [Abstract][Full Text] [Related]
15. Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease.
Park SH; Kim HJ; Lee CK; Song EM; Kang SB; Jang BI; Kim ES; Kim KO; Lee YJ; Kim EY; Jung YJ; Park SK; Park DI; Ye BD; Jung SA; Yang SK
J Crohns Colitis; 2020 Dec; 14(12):1780-1784. PubMed ID: 32417881
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response.
Sheibani S; Cohen R; Kane S; Dubinsky M; Church JA; Mahadevan U
Dig Dis Sci; 2016 Jun; 61(6):1622-7. PubMed ID: 26725061
[TBL] [Abstract][Full Text] [Related]
17. In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration.
Berkhout A; Clark JE; Wen SC
Expert Rev Vaccines; 2019 May; 18(5):495-504. PubMed ID: 30916600
[TBL] [Abstract][Full Text] [Related]
18. Management of inflammatory bowel disease and serum level of infliximab in newborn exposed to anti-TNF therapy during pregnancy: Case report and literature review.
de Aragão MC; Beraldo RF; Marcondes MB; de Barros JR; Herrerias GSP; Saad-Hossne R; Baima JP; Sassaki LY
Medicine (Baltimore); 2021 Dec; 100(51):e28274. PubMed ID: 34941109
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
